Pomalidomide in relapsed/refractory multiple myeloma

In this study, researchers evaluated the efficacy and safety of pomalidomide in the combined treatment of relapsed/refractory multiple myeloma. In all, data from 31 clinical trials were reviewed, involving a total of 4,776 patients. Combination regimens with pomalidomide showed good clinical efficacy, particularly the combination of pomalidomide and dexamethasone. In terms of safety, the most frequent grade ≥ 3 hematological adverse events were neutropenia (41%) and anemia (20%). Non-hematological adverse events were pneumonia (14%) and infection/febrile neutropenia (14%). While the clinical efficacy of pomalidomide appears interesting, its hematological toxicity calls for particular vigilance.